Literature DB >> 3453828

A case of variant angina exacerbated by administration of rifampicin.

K Tsuchihashi1, K Fukami, H Kishimoto, T Sumiyoshi, K Haze, M Saito, K Hiramori.   

Abstract

Rifampicin, an antituberculosis agent, is known to be a potent inducer of microsomal drug-metabolizing enzymes in the liver. Elimination or clearance of many drugs has been reported to be enhanced, and their effectiveness reduced; however, no report in the literature has dealt with the interaction between rifampicin and dihydropiridine calcium entry-blocking drugs such as nifedipine. We present here evidence for the possible interaction between rifampicin and nifedipine in a patient with angina pectoris, which was exacerbated during coadministration or rechallenge with rifampicin. The peak plasma level and area under the curve were reduced and the apparent oral clearance of nifedipine was increased by rifampicin, suggesting that rifampicin enhanced the elimination of nifedipine via induction of a hepatic microsomal drug-metabolizing enzyme, as has been reported on other drugs widely metabolized in the liver.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3453828     DOI: 10.1007/BF02058314

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  16 in total

1.  [Effects of rifampicin on the menstrual cycle and on oestrogen excretion in patients taking oral contraceptives].

Authors:  L Nocke-Finck; H Breuer; D Reimers
Journal:  Dtsch Med Wochenschr       Date:  1973-08-11       Impact factor: 0.628

2.  [The effects of antituberculosis drugs on the pharmacokinetics of digitoxin (author's transl)].

Authors:  U Peters; T U Hausamen; F Grosse-Brockhoff
Journal:  Dtsch Med Wochenschr       Date:  1974-11-22       Impact factor: 0.628

3.  Letter: Rifampicin and cortisone replacement therapy.

Authors:  D N Maisey; R C Brown; J L Day
Journal:  Lancet       Date:  1974-10-12       Impact factor: 79.321

4.  Interaction of sodium warfarin and rifampin. Studies in man.

Authors:  R A O'Reilly
Journal:  Ann Intern Med       Date:  1974-09       Impact factor: 25.391

Review 5.  Clinical pharmacology of slow channel blocking agents.

Authors:  R G McAllister
Journal:  Prog Cardiovasc Dis       Date:  1982 Sep-Oct       Impact factor: 8.194

6.  Quinidine-rifampin interaction.

Authors:  Y Twum-Barima; S G Carruthers
Journal:  N Engl J Med       Date:  1981-06-11       Impact factor: 91.245

Review 7.  Rifampin drug interactions.

Authors:  A M Baciewicz; T H Self
Journal:  Arch Intern Med       Date:  1984-08

8.  Hemodynamic evaluation of isosorbide dinitrate in alcoholic cirrhosis. Pharmacokinetic-hemodynamic interactions.

Authors:  A T Blei; G Garcia-Tsao; R J Groszmann; P Kahrilas; D Ganger; S Morse; H L Fung
Journal:  Gastroenterology       Date:  1987-09       Impact factor: 22.682

9.  Effect of rifampicin on metoprolol and antipyrine kinetics.

Authors:  P N Bennett; V A John; V B Whitmarsh
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

10.  Changes of the smooth endoplasmic reticulum induced by rifampicin in human and guinea-pig hepatocytes.

Authors:  A M Jezequel; F Orlandi; L T Tenconi
Journal:  Gut       Date:  1971-12       Impact factor: 23.059

View more
  4 in total

Review 1.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

2.  Effect of rifampin on enantioselective disposition and anti-hypertensive effect of benidipine.

Authors:  Yu Eun Sunwoo; Phuong Thi Thu Nguyen; Chin May Chien; Ji Young Ryu; Jihong Shon; Jae-Gook Shin
Journal:  Br J Clin Pharmacol       Date:  2019-01-30       Impact factor: 4.335

Review 3.  Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.

Authors:  F Pea; M Furlanut
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

4.  Rifampicin and anti-hypertensive drugs in chronic kidney disease: Pharmacokinetic interactions and their clinical impact.

Authors:  A Agrawal; S K Agarwal; T Kaleekal; Y K Gupta
Journal:  Indian J Nephrol       Date:  2016-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.